CAJ | 학술논문

目的比较根治性切除术后小肝癌患者辅助folfox4方案化疗和无辅助化疗组肿瘤复发率和生存率间差异,探索降低肝癌术后复发的措施.方法分析本院2006年4月至2012年10月符合纳入标准根治性切除术后的小肝癌患者97例,行辅助folfox4方案化疗46例为化疗组,无辅助化疗51例为对照组,比较2组患者的复发率和生存率.结果 2组患者的临床病理资料差异无统计学意义,化疗组1、2、3、4、5年无瘤生存率为89％、70％、59％、48％、35％;对照组1、2、3、4、5年无瘤生存率为78％、65％、53％、37％、27％,差异无统计学意义(P =0.459).化疗组1、2、3、4、5年生存率为96％、76％、63％、57％、52％;对照组1、2、3、4、5年生存率为96％、73％、59％、51％、47％,差异无统计学意义(P=0.712).COX风险回归亦显示folfox4方案辅助化疗不是肿瘤复发和预后独立的影响因素(分别P值=0.467,0.834).结论对于直径＜5 cm的肝细胞癌患者,根治性切除术后予folfox4辅助化疗不能降低肿瘤复发率和改善总体生存率.
목적 비교근치성절제술후소간암환자보조folfox4방안화료화무보조화료조종류복발솔화생존솔간차이,탐색강저간암술후복발적조시.방법 분석본원2006년4월지2012년10월부합납입표준근치성절제술후적소간암환자97례,행보조folfox4방안화료46례위화료조,무보조화료51례위대조조,비교2조환자적복발솔화생존솔.결과 2조환자적림상병리자료차이무통계학의의,화료조1、2、3、4、5년무류생존솔위89％、70％、59％、48％、35％;대조조1、2、3、4、5년무류생존솔위78％、65％、53％、37％、27％,차이무통계학의의(P =0.459).화료조1、2、3、4、5년생존솔위96％、76％、63％、57％、52％;대조조1、2、3、4、5년생존솔위96％、73％、59％、51％、47％,차이무통계학의의(P=0.712).COX풍험회귀역현시folfox4방안보조화료불시종류복발화예후독립적영향인소(분별P치=0.467,0.834).결론 대우직경＜5 cm적간세포암환자,근치성절제술후여folfox4보조화료불능강저종류복발솔화개선총체생존솔.
Objective To compare the recmrence and survival rate between small hepatocellular carcinoma (HCC)patients with and without folfox4 adjuvant chemotherapy after radical resection.Methods From April 2006 to October 2012 46 HCC eases after curative resection received folfox4 adjuvant chemotherapy, 51 cases served as control.Results The clinical and pathological data of the two groups were not significantly different.The 1, 2, 3, 4, 5-year disease-free survival of the group with folfox4 adjuvant chemotherapy was 89％ , 70％ , 59％ , 48％ , 35％ ,and that was 78％ , 65％ , 53％ , 37％ , 27％in control group, the difference was not statistically significant (P =0.459).The 1, 2, 3,4, 5-year overall survival rate of the group with folfox4 adjuvant chemotherapy was 96％ , 76％ , 63％ , 57％ , 52％ , that in control group was 96％ , 73％ , 59％ , 51％ , 47％ , the difference was not statistically significant (P =0.459).COX-hazards regression showed folfox4 adjuvant chemotherapy was not independent factors of recurrence and prognosis (P =0.467, P =0.834).Conclusions For patients with hepatocellular carcinoma smaller than 5 cm in diameter,folfox4 adjuvant chemotherapy after radical resection did not reduce the recurrence rate and did not improve survival.